Stefanos Bonovas1,2, Georgios K Nikolopoulos3, Theodore Lytras4,5,6, Gionata Fiorino2, Laurent Peyrin-Biroulet7, Silvio Danese1,2. 1. Department of Biomedical Sciences, Humanitas University, Milan, Italy. 2. IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy. 3. Medical School, University of Cyprus, Nicosia, Cyprus. 4. Hellenic Center for Disease Control and Prevention, Athens, Greece. 5. Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain. 6. Barcelona Institute for Global Health, Barcelona, Spain. 7. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Abstract
AIMS: Oral systemic corticosteroids have been used to induce remission in patients with active inflammatory bowel disease (IBD) for over 50 years; however, the wide array of adverse events (AEs) associated with these drugs prompted the development of steroid compounds with targeted delivery and low systemic bioavailability. This study assessed corticosteroids' comparative harm using network meta-analysis. METHODS: We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory authorities' websites and major conference proceedings, through March 2017. Randomized controlled trials that recruited adult IBD patients and compared oral systemic corticosteroids (prednisone/prednisolone) or compounds/formulations with low systemic bioavailability (budesonide, budesonide MMX, and beclomethasone dipropionate) with placebo, or against each other, were considered eligible for inclusion. Two reviewers independently extracted study data and outcomes, and rated each trial's risk-of-bias. RESULTS: We identified and synthesized evidence from 31 trials including 5689 IBD patients. Budesonide MMX was associated with significantly fewer corticosteroid-related AEs than oral systemic corticosteroids [odds ratio (OR): 0.25, 95% confidence interval (CI): 0.13-0.49] and beclomethasone (OR: 0.35, 95% CI: 0.13-1.00), but not significantly fewer AEs than budesonide (OR: 0.64, 95% CI: 0.37-1.11); it performed equally good with placebo. By contrast, the occurrence of serious AEs, and treatment discontinuations due to AEs, did not differ between the comparator treatments. CONCLUSIONS: Budesonide MMX is associated with fewer corticosteroid-related AEs than its comparator steroid treatments for adult IBD patients. Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles.
AIMS: Oral systemic corticosteroids have been used to induce remission in patients with active inflammatory bowel disease (IBD) for over 50 years; however, the wide array of adverse events (AEs) associated with these drugs prompted the development of steroid compounds with targeted delivery and low systemic bioavailability. This study assessed corticosteroids' comparative harm using network meta-analysis. METHODS: We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory authorities' websites and major conference proceedings, through March 2017. Randomized controlled trials that recruited adult IBDpatients and compared oral systemic corticosteroids (prednisone/prednisolone) or compounds/formulations with low systemic bioavailability (budesonide, budesonide MMX, and beclomethasone dipropionate) with placebo, or against each other, were considered eligible for inclusion. Two reviewers independently extracted study data and outcomes, and rated each trial's risk-of-bias. RESULTS: We identified and synthesized evidence from 31 trials including 5689 IBDpatients. Budesonide MMX was associated with significantly fewer corticosteroid-related AEs than oral systemic corticosteroids [odds ratio (OR): 0.25, 95% confidence interval (CI): 0.13-0.49] and beclomethasone (OR: 0.35, 95% CI: 0.13-1.00), but not significantly fewer AEs than budesonide (OR: 0.64, 95% CI: 0.37-1.11); it performed equally good with placebo. By contrast, the occurrence of serious AEs, and treatment discontinuations due to AEs, did not differ between the comparator treatments. CONCLUSIONS:Budesonide MMX is associated with fewer corticosteroid-related AEs than its comparator steroid treatments for adult IBDpatients. Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles.
Authors: R Löfberg; A Danielsson; O Suhr; A Nilsson; R Schiöler; A Nyberg; R Hultcrantz; B Kollberg; R Gillberg; R Willén; T Persson; L Salde Journal: Gastroenterology Date: 1996-06 Impact factor: 22.682
Authors: William J Sandborn; Simon Travis; Luigi Moro; Richard Jones; Theres Gautille; Robert Bagin; Michael Huang; Phil Yeung; E David Ballard Journal: Gastroenterology Date: 2012-08-11 Impact factor: 22.682
Authors: Erik J Schoon; Simona Bollani; Peter R Mills; Eran Israeli; Dieter Felsenberg; Sverker Ljunghall; Tore Persson; Louise Haptén-White; Hans Graffner; Gabriele Bianchi Porro; Morten Vatn; Reinhold W Stockbrügger Journal: Clin Gastroenterol Hepatol Date: 2005-02 Impact factor: 11.382
Authors: Aysha H Al-Ani; Ralley E Prentice; Clarissa A Rentsch; Doug Johnson; Zaid Ardalan; Neel Heerasing; Mayur Garg; Sian Campbell; Joe Sasadeusz; Finlay A Macrae; Siew C Ng; David T Rubin; Britt Christensen Journal: Aliment Pharmacol Ther Date: 2020-05-26 Impact factor: 9.524